Nuvation Bio Inc. (NUVB) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nuvation Bio Inc. (NUVB:NYSE), powered by AI.

Current Price
$5.12
Sector
Healthcare
What is the Nuvation Bio Inc. stock price forecast?

Nuvation Bio Inc. is currently trading at $5.12. View real-time AI analysis on Alpha Lenz.

What is Nuvation Bio Inc. insider trading activity?

View the latest insider trading data for Nuvation Bio Inc. on Alpha Lenz.

What is Nuvation Bio Inc.'s P/E ratio?

View Nuvation Bio Inc.'s valuation metrics on Alpha Lenz.

Nuvation Bio Inc.

NYSE · NUVB
$5.12-0.02(-0.39%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Nuvation Bio Inc.'s future dividend policy...
Alpha Chat Insight

Nuvation Bio Inc.'s ROE is -53.2%. Explore profitability and growth together.

Ask for details

Company Overview

Nuvation Bio Inc. is a biopharmaceutical company focused on developing innovative therapies for oncology patients. Its primary purpose is to research and advance novel drug candidates targeting various forms of cancer, particularly those for which few treatments currently exist. The company's pipeline is centered on next-generation therapies, including small molecules and targeted drugs designed to enhance and extend the lives of cancer patients. Operating in the highly competitive and scientifically rigorous field of biotechnology, Nuvation Bio Inc. collaborates with leading experts in oncological research to bring promising treatments to clinical trials. Its strategic focus on areas like neuroendocrine tumors and advanced prostate cancer highlights its dedication to addressing unmet medical needs. In the financial markets, Nuvation Bio Inc. holds significance due to its potential impact on the healthcare sector, particularly through the development of breakthrough cancer therapies that could transform treatment paradigms. The company's progress is closely followed by investors and stakeholders interested in the future of cancer treatment innovation.

CEODr. David T. Hung M.D.
SectorHealthcare
IndustryBiotechnology
Employees278

Company Statistics

FY 2025

Profile

N/AMarket Cap
$62.90MRevenue
0.00Shares Out
278Employees

Margins

85.22%Gross
-299.46%EBITDA
-338.72%Operating
-325.31%Pre-Tax
-325.31%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-36.04%ROA
-53.18%ROE
-33.63%ROIC

Financial Health

$164.09MCash & Cash Equivalents
$125.02MNet Debt
94.57%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Nuvation Bio Inc. (ticker: NUVB) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 278 employees.

The current price is $5.12 with a P/E ratio of -x and P/B of -x.

ROE is -53.18% and operating margin is -338.72%. Annual revenue is $63M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Nuvation Bio Inc. (NUVB) Stock Forecast 2026 $5.12 — Price, Financials & Analyst Targets | Alpha Lenz